| Authors | نگار مشایخ,الهه محمودی خالدی |
| Journal | Sensing and Bio-Sensing Research |
| IF | ثبت نشده |
| Paper Type | Full Paper |
| Published At | 2026-03-03 |
| Journal Grade | Scientific - research |
| Journal Type | Electronic |
| Journal Country | Iran, Islamic Republic Of |
| Journal Index | JCR ,SCOPUS |
| Keywords | Biosensors; Nanomaterials; Point, of, care diagnostics; Electrochemical and optical sensing; Communicable and non, communicable diseases; Biomarker detection |
|---|
Abstract
Biosensors have become crucial analytical tools in modern medicine, attracting scientists’
attention. They offer rapid, sensitive, and cost-effective detection of disease biomarkers. This
review provides a critical overview and summarizes biosensor components and transduction
modes, evolution, and clinical applications, with a focus on communicable and non-communicable
diseases. The progression from early enzyme electrodes to nanomaterial-enabled electrochemical
and optical platforms, alongside microfluidic and wearable formats, has expanded capabilities for
point-of-care testing and longitudinal data acquisition. Clinically approved biosensors, such as
those for glucose, cardiac troponins, and prostate-specific antigen illustrate that the translation of
biosensor research into practical healthcare solutions is feasible under appropriate regulations and
holds a promise for the future to come. Recent developments in electrochemical, microfluidic, and
Surface Plasmon Resonance (SPR)-based sensing support multiplexed and miniaturized systems
aimed at point-of-care testing and, in some cases, continuous monitoring. By presenting FDA-
cleared and CE-marked platforms, specifically for NCDs, and comparing them with clinically
approved CD assays, we highlight a persistent translational gap. Despite existing challenges in
sensor stability, matrix effect, biofouling, calibration, manufacturability, and large-scale clinical
validation, the integration of biosensors with nanotechnology, artificial intelligence, and wireless
communication holds promise for the next generation of personalized, decentralized healthcare.
We also discuss how the use of AI/ML for longitudinal signals, sustainable design, and alignment
with One Health perspective collectively shape translation from lab-ready sensors to clinically
adopted systems. Overall, biosensors represent a powerful convergence of biology and engineering
that is reshaping diagnostic medicine and enabling more accessible, real-time, and patient-centered
health management.